MiR-195 Inhibits Tumor Growth and Metastasis in Papillary Thyroid Carcinoma Cell Lines by Targeting CCND1 and FGF2

Background. MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the large data set analysis from The Cancer Genome Atlas (TCGA). Our study aimed to explore the biological functions and the underlying molecular...

Full description

Saved in:
Bibliographic Details
Published inInternational Journal of Endocrinology Vol. 2017; no. 2017; pp. 1 - 12
Main Authors Xiao, Haipeng, Li, Yanbing, Liu, Yujie, Chen, Shuwei, Huang, Yanrui, Yu, Shuang, Hong, Shubin, Yin, Yali, Zhang, Quan
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Limiteds 01.01.2017
Hindawi Publishing Corporation
Hindawi
John Wiley & Sons, Inc
Wiley
Subjects
Antibodies
Antigens
Cell adhesion & migration
Cloning
Development and progression
Endocrinology
Genes
Genetic aspects
Medical prognosis
Metastasis
MicroRNA
MicroRNAs
Pathogenesis
Plasmids
Thyroid cancer
United States > US
Switzerland
China
Germany
Online AccessGet full text

Cover

Abstract Background. MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the large data set analysis from The Cancer Genome Atlas (TCGA). Our study aimed to explore the biological functions and the underlying molecular mechanisms of miR-195 in PTC. Methods. The relative expression of miR-195 and its target genes were assessed by quantitative RT-PCR assay in 38 pairs of PTC and the adjacent thyroid tissues. Assays were performed to evaluate the effect of miR-195 on the proliferation, migration, and invasion in PTC cell lines. Moreover, we searched for targets of miR-195 and explored the possible molecular pathway of miR-195 in PTC. Results. We found that miR-195 was downregulated in PTC cell lines and tissues. Overexpression of miR-195 significantly inhibited cell proliferation, migration, and invasion in K1 and BCPAP cell lines. CCND1 and FGF2, which had inverse correlations with miR-195 in clinical specimens, were found to be the direct targets of miR-195. Furthermore, miR-195 might be involved in PTC tumorigenesis by suppressing the Wnt/β-catenin signaling pathway. Conclusions. These results highlight an important role of miR-195 in the initiation and progression of PTC and implicate the potential application of miR-195 in PTC target therapy.
AbstractList MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and was verified to be downregulated in PTC by the large data set analysis from The Cancer Genome Atlas (TCGA). Our study aimed to explore the biological functions and the underlying molecular mechanisms of in PTC. The relative expression of and its target genes were assessed by quantitative RT-PCR assay in 38 pairs of PTC and the adjacent thyroid tissues. Assays were performed to evaluate the effect of on the proliferation, migration, and invasion in PTC cell lines. Moreover, we searched for targets of and explored the possible molecular pathway of in PTC. We found that was downregulated in PTC cell lines and tissues. Overexpression of significantly inhibited cell proliferation, migration, and invasion in K1 and BCPAP cell lines. and , which had inverse correlations with in clinical specimens, were found to be the direct targets of . Furthermore, might be involved in PTC tumorigenesis by suppressing the Wnt/ -catenin signaling pathway. These results highlight an important role of in the initiation and progression of PTC and implicate the potential application of in PTC target therapy.
Background. MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the large data set analysis from The Cancer Genome Atlas (TCGA). Our study aimed to explore the biological functions and the underlying molecular mechanisms of miR-195 in PTC. Methods. The relative expression of miR-195 and its target genes were assessed by quantitative RT-PCR assay in 38 pairs of PTC and the adjacent thyroid tissues. Assays were performed to evaluate the effect of miR-195 on the proliferation, migration, and invasion in PTC cell lines. Moreover, we searched for targets of miR-195 and explored the possible molecular pathway of miR-195 in PTC. Results. We found that miR-195 was downregulated in PTC cell lines and tissues. Overexpression of miR-195 significantly inhibited cell proliferation, migration, and invasion in K1 and BCPAP cell lines. CCND1 and FGF2, which had inverse correlations with miR-195 in clinical specimens, were found to be the direct targets of miR-195. Furthermore, miR-195 might be involved in PTC tumorigenesis by suppressing the Wnt/β-catenin signaling pathway. Conclusions. These results highlight an important role of miR-195 in the initiation and progression of PTC and implicate the potential application of miR-195 in PTC target therapy.
Background. MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the large data set analysis from The Cancer Genome Atlas (TCGA). Our study aimed to explore the biological functions and the underlying molecular mechanisms of miR-195 in PTC. Methods. The relative expression of miR-195 and its target genes were assessed by quantitative RT-PCR assay in 38 pairs of PTC and the adjacent thyroid tissues. Assays were performed to evaluate the effect of miR-195 on the proliferation, migration, and invasion in PTC cell lines. Moreover, we searched for targets of miR-195 and explored the possible molecular pathway of miR-195 in PTC. Results. We found that miR-195 was downregulated in PTC cell lines and tissues. Overexpression of miR-195 significantly inhibited cell proliferation, migration, and invasion in K1 and BCPAP cell lines. CCND1 and FGF2, which had inverse correlations with miR195 in clinical specimens, were found to be the direct targets of miR-195. Furthermore, miR-195 might be involved in PTC tumorigenesis by suppressing the Wnt/[beta]-catenin signaling pathway. Conclusions. These results highlight an important role of miR-195 in the initiation and progression of PTC and implicate the potential application of miR-195 in PTC target therapy.
Background . MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the large data set analysis from The Cancer Genome Atlas (TCGA). Our study aimed to explore the biological functions and the underlying molecular mechanisms of miR-195 in PTC. Methods . The relative expression of miR-195 and its target genes were assessed by quantitative RT-PCR assay in 38 pairs of PTC and the adjacent thyroid tissues. Assays were performed to evaluate the effect of miR-195 on the proliferation, migration, and invasion in PTC cell lines. Moreover, we searched for targets of miR-195 and explored the possible molecular pathway of miR-195 in PTC. Results . We found that miR-195 was downregulated in PTC cell lines and tissues. Overexpression of miR-195 significantly inhibited cell proliferation, migration, and invasion in K1 and BCPAP cell lines. CCND1 and FGF2 , which had inverse correlations with miR-195 in clinical specimens, were found to be the direct targets of miR-195 . Furthermore, miR-195 might be involved in PTC tumorigenesis by suppressing the Wnt/ β -catenin signaling pathway. Conclusions . These results highlight an important role of miR-195 in the initiation and progression of PTC and implicate the potential application of miR-195 in PTC target therapy.
MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the large data set analysis from The Cancer Genome Atlas (TCGA). Our study aimed to explore the biological functions and the underlying molecular mechanisms of miR-195 in PTC.BACKGROUNDMicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the large data set analysis from The Cancer Genome Atlas (TCGA). Our study aimed to explore the biological functions and the underlying molecular mechanisms of miR-195 in PTC.The relative expression of miR-195 and its target genes were assessed by quantitative RT-PCR assay in 38 pairs of PTC and the adjacent thyroid tissues. Assays were performed to evaluate the effect of miR-195 on the proliferation, migration, and invasion in PTC cell lines. Moreover, we searched for targets of miR-195 and explored the possible molecular pathway of miR-195 in PTC.METHODSThe relative expression of miR-195 and its target genes were assessed by quantitative RT-PCR assay in 38 pairs of PTC and the adjacent thyroid tissues. Assays were performed to evaluate the effect of miR-195 on the proliferation, migration, and invasion in PTC cell lines. Moreover, we searched for targets of miR-195 and explored the possible molecular pathway of miR-195 in PTC.We found that miR-195 was downregulated in PTC cell lines and tissues. Overexpression of miR-195 significantly inhibited cell proliferation, migration, and invasion in K1 and BCPAP cell lines. CCND1 and FGF2, which had inverse correlations with miR-195 in clinical specimens, were found to be the direct targets of miR-195. Furthermore, miR-195 might be involved in PTC tumorigenesis by suppressing the Wnt/β-catenin signaling pathway.RESULTSWe found that miR-195 was downregulated in PTC cell lines and tissues. Overexpression of miR-195 significantly inhibited cell proliferation, migration, and invasion in K1 and BCPAP cell lines. CCND1 and FGF2, which had inverse correlations with miR-195 in clinical specimens, were found to be the direct targets of miR-195. Furthermore, miR-195 might be involved in PTC tumorigenesis by suppressing the Wnt/β-catenin signaling pathway.These results highlight an important role of miR-195 in the initiation and progression of PTC and implicate the potential application of miR-195 in PTC target therapy.CONCLUSIONSThese results highlight an important role of miR-195 in the initiation and progression of PTC and implicate the potential application of miR-195 in PTC target therapy.
Audience Academic
Author Yin, Yali
Yu, Shuang
Xiao, Haipeng
Chen, Shuwei
Liu, Yujie
Zhang, Quan
Li, Yanbing
Huang, Yanrui
Hong, Shubin
AuthorAffiliation 3 State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
2 Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
1 Department of Endocrinology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
4 Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
AuthorAffiliation_xml – name: 4 Breast Tumor Center, Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University, Guangzhou 510120, China
– name: 3 State Key Laboratory of Oncology in South China, Collaborative Innovation Center of Cancer Medicine, Guangzhou, China
– name: 2 Department of Head and Neck Surgery, Sun Yat-Sen University Cancer Center, Guangzhou 510060, China
– name: 1 Department of Endocrinology, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, China
Author_xml – sequence: 1
  fullname: Xiao, Haipeng
– sequence: 2
  fullname: Li, Yanbing
– sequence: 3
  fullname: Liu, Yujie
– sequence: 4
  fullname: Chen, Shuwei
– sequence: 5
  fullname: Huang, Yanrui
– sequence: 6
  fullname: Yu, Shuang
– sequence: 7
  fullname: Hong, Shubin
– sequence: 8
  fullname: Yin, Yali
– sequence: 9
  fullname: Zhang, Quan
BackLink https://www.ncbi.nlm.nih.gov/pubmed/28740507$$D View this record in MEDLINE/PubMed
BookMark eNqFkttrFDEUxgep2Iu--SwBQQTdNieT27wIZbW10GqR-hyyM5mdlNlkTWYt_e89e-lliyITkkzyO1_O-Tj7xU6IwRXFa6CHAEIcMQrqSIKmnIlnxR5IrUa65GLnfl-q3WI_52tKpZQUXhS7TCtOBVV7RbrwP0ZQCXIWOj_xQyZXi1lM5DTFm6EjNjTkwg024_CZ-EAu7dz3vU235Kq7TdE3ZGxT7UOcWTJ2fU_OfXCZTPDepqkbfJiS8fjbZ1hpnZyesJfF89b22b3arAfFz5MvV-Ovo_Pvp2fj4_ORlVINIyWallmtqLaNphPVKKZpaUtXTRjn1JZKa8eZ5lpVXCqhQZStBAclFseBlgfF2Vq3ifbazJOfYdYmWm9WBzFNjU2Dr3tnRM20s6VsdQ28nQhteQmqrJTCWXNArU9rrfliMnNN7cKQbL8lun0TfGem8bcRgvKqZCjwfiOQ4q-Fy4OZ-VyjXza4uMgGKlYCpi40om-foNdxkQJaZRjWxTVIKR6oqcUCfGgjvlsvRc2x4JQK0BVH6vAvFH6Nm_kaG6n1eL4V8O5RQOdsP3Q59ovBx5C3wTePHbm34q61EGBroE4x5-RaU_vBLnUwBd8boGbZv2bZv2bTvxj08UnQne4_8A9rvPOhsTf-f_QmZYeMa-0DjY7yaglcrAHrkx_8g--XqCNpBRWlbKUJq0UDUKD06Q8YnCh69AfJgRPR
CitedBy_id crossref_primary_10_3892_ol_2019_11100
crossref_primary_10_3892_br_2019_1256
crossref_primary_10_1177_2058738418772652
crossref_primary_10_1186_s12935_020_01327_3
crossref_primary_10_1002_jbt_23498
crossref_primary_10_18632_aging_202219
crossref_primary_10_3389_fonc_2023_1145082
crossref_primary_10_1002_tox_23761
crossref_primary_10_1007_s10555_023_10142_x
crossref_primary_10_1186_s13104_024_06876_8
crossref_primary_10_1111_jcmm_14386
crossref_primary_10_1186_s12957_019_1755_9
crossref_primary_10_3390_cells12071002
crossref_primary_10_1007_s40618_023_02241_x
crossref_primary_10_1002_jcb_27993
crossref_primary_10_1080_21655979_2021_2008639
crossref_primary_10_1016_j_lfs_2020_119005
crossref_primary_10_1049_iet_syb_2019_0025
crossref_primary_10_2147_CMAR_S266807
crossref_primary_10_3390_jcm11082130
crossref_primary_10_1016_j_jep_2024_117908
crossref_primary_10_1155_2018_1505307
crossref_primary_10_1016_j_biopha_2018_08_150
crossref_primary_10_1186_s13046_018_0936_7
crossref_primary_10_3892_mmr_2019_10717
crossref_primary_10_1016_j_semcancer_2021_03_026
crossref_primary_10_1002_kjm2_12236
crossref_primary_10_3389_fonc_2021_755097
crossref_primary_10_1042_BSR20190083
crossref_primary_10_1186_s40364_022_00382_4
crossref_primary_10_3390_pharmaceutics15082061
crossref_primary_10_3892_mmr_2019_10315
crossref_primary_10_1016_j_taap_2023_116652
crossref_primary_10_1016_j_biopha_2017_11_146
crossref_primary_10_1002_cam4_3062
crossref_primary_10_3390_cancers12010129
crossref_primary_10_3892_mmr_2018_9119
crossref_primary_10_3390_cancers12113264
crossref_primary_10_1002_jcb_29604
crossref_primary_10_3390_biomedicines12122829
crossref_primary_10_1016_j_ebiom_2020_102941
crossref_primary_10_1038_s41598_018_28299_9
crossref_primary_10_2174_0929866530666230804104057
crossref_primary_10_1007_s12672_025_01993_7
crossref_primary_10_3892_wasj_2020_51
Cites_doi 10.1371/journal.pone.0144073
10.1158/1055-9965.EPI-13-0242
10.1210/jc.2011-3059
10.1038/sj.onc.1210055
10.1016/S0002-9440(10)64045-X
10.1101/gad.14.15.1837
10.1016/j.cell.2009.01.002
10.3322/caac.21338
10.1016/j.devcel.2009.06.016
10.1002/hep.26373
10.4161/cc.20898
10.1038/sj.onc.1210056
10.1016/j.canlet.2013.01.028
10.1002/hep.22919
10.1210/jcem.87.7.8648
10.1210/jcem.80.3.7533768
10.1016/j.molcel.2011.06.020
10.1038/nm.1880
10.2147/OTT.S85753
10.1158/0008-5472.CAN-12-2651
10.1016/S0065-230X(08)60305-X
10.1038/sj.onc.1204123
10.1177/172460081002500106
10.1038/ncb3222
10.1210/jc.2002-021113
10.1210/jc.2012-2666
10.1667/RR13784.1
10.1111/j.1440-1746.2005.03726.x
10.1089/thy.2015.0578
10.1158/1055-9965.EPI-08-0960
10.1016/S0002-9440(10)65549-6
10.1002/cncr.28254
10.1002/hep.26378
10.1007/s10552-008-9260-4
10.1210/jc.2005-0285
10.1016/S0169-5002(01)00225-2
10.1210/jc.2013-1214
10.1089/105072501300042802
10.1007/s13277-014-2822-z
10.1080/23723556.2015.1109744
10.1677/ERC-07-0129
ContentType Journal Article
Copyright Copyright © 2017 Yali Yin et al.
COPYRIGHT 2017 John Wiley & Sons, Inc.
Copyright © 2017 Yali Yin et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright © 2017 Yali Yin et al. 2017
Copyright_xml – notice: Copyright © 2017 Yali Yin et al.
– notice: COPYRIGHT 2017 John Wiley & Sons, Inc.
– notice: Copyright © 2017 Yali Yin et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: Copyright © 2017 Yali Yin et al. 2017
DBID 188
ADJCN
AHFXO
RHU
RHW
RHX
AAYXX
CITATION
NPM
3V.
7X7
7XB
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1155/2017/6180425
DatabaseName Chinese Electronic Periodical Services (CEPS)
الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals
معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete
Hindawi Publishing Complete
Hindawi Publishing Subscription Journals
Hindawi Publishing Open Access
CrossRef
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
ProQuest Central Premium
ProQuest One Academic
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
Directory of Open Access Journals - May need to register for free articles
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList PubMed


CrossRef
Publicly Available Content Database
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: RHX
  name: Hindawi Publishing Open Access
  url: http://www.hindawi.com/journals/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Anatomy & Physiology
EISSN 1687-8345
Editor Damante, Giuseppe
Editor_xml – sequence: 1
  givenname: Giuseppe
  surname: Damante
  fullname: Damante, Giuseppe
EndPage 12
ExternalDocumentID oai_doaj_org_article_5c28ea36f8c14fb58a43173977173841
PMC5504932
A540051894
28740507
10_1155_2017_6180425
1166495
P20160919002_201712_201811010012_201811010012_1_12_094
Genre Journal Article
GeographicLocations United States--US
Switzerland
China
Germany
GeographicLocations_xml – name: Switzerland
– name: China
– name: Germany
– name: United States--US
GrantInformation_xml – fundername: National Natural Science Foundation of China
  grantid: 81472500
– fundername: Medical Scientific Research Foundation of Guangdong Province
  grantid: A2016065
– fundername: Finance Department Foundation of Guangdong Province
  grantid: 20160902
GroupedDBID ---
188
24P
29J
2UF
2WC
4.4
53G
5GY
5VS
7X7
8FI
8FJ
AAFWJ
AAJEY
AAWTL
ABDBF
ABUWG
ACGFO
ADBBV
ADRAZ
AEGXH
AENEX
AFKRA
AFPKN
AINHJ
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AOIJS
BAWUL
BCNDV
BENPR
CCPQU
CEFSP
CNMHZ
DIK
E3Z
EBD
EBS
EJD
ESX
F5P
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
IEA
IHR
IHW
ITC
KQ8
M48
O5R
O5S
OK1
PGMZT
PIMPY
RHU
RHX
RNS
RPM
TR2
TUS
UKHRP
UZ5
~8M
ADJCN
AHFXO
C1A
IL9
RHW
0R~
AAYXX
ACCMX
ACUHS
CITATION
PHGZM
PHGZT
NPM
PMFND
3V.
7XB
8FK
AAMMB
AEFGJ
AGXDD
AIDQK
AIDYY
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
PUEGO
ID FETCH-LOGICAL-a667t-75df2a8708ad80b7d72803a3e9b2440a3788e428487946758153f61e138744103
IEDL.DBID M48
ISSN 1687-8337
IngestDate Wed Aug 27 01:31:35 EDT 2025
Thu Aug 21 17:44:20 EDT 2025
Fri Jul 11 06:12:20 EDT 2025
Sun Jul 13 05:09:28 EDT 2025
Tue Jun 17 22:03:08 EDT 2025
Tue Jun 10 21:02:26 EDT 2025
Thu May 22 21:27:23 EDT 2025
Wed Feb 19 02:00:58 EST 2025
Tue Jul 01 03:54:32 EDT 2025
Thu Apr 24 22:53:42 EDT 2025
Sun Jun 02 18:53:33 EDT 2024
Tue Nov 26 16:45:03 EST 2024
Tue Oct 01 22:51:42 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2017
Language English
License This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
http://creativecommons.org/licenses/by/4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a667t-75df2a8708ad80b7d72803a3e9b2440a3788e428487946758153f61e138744103
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
Academic Editor: Giuseppe Damante
ORCID 0000-0003-2660-2790
0000-0001-5147-1302
0000-0002-0199-7549
0000-0003-0918-8655
0000-0002-6990-2649
0000-0002-4188-336X
0000-0001-5377-7727
0000-0001-7365-7896
0000-0001-7242-760X
OpenAccessLink http://journals.scholarsportal.info/openUrl.xqy?doi=10.1155/2017/6180425
PMID 28740507
PQID 2410481665
PQPubID 4727234
PageCount 12
ParticipantIDs doaj_primary_oai_doaj_org_article_5c28ea36f8c14fb58a43173977173841
pubmedcentral_primary_oai_pubmedcentral_nih_gov_5504932
proquest_miscellaneous_1923113858
proquest_journals_2410481665
gale_infotracmisc_A540051894
gale_infotracacademiconefile_A540051894
gale_healthsolutions_A540051894
pubmed_primary_28740507
crossref_citationtrail_10_1155_2017_6180425
crossref_primary_10_1155_2017_6180425
hindawi_primary_10_1155_2017_6180425
emarefa_primary_1166495
airiti_journals_P20160919002_201712_201811010012_201811010012_1_12_094
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2017-01-01
PublicationDateYYYYMMDD 2017-01-01
PublicationDate_xml – month: 01
  year: 2017
  text: 2017-01-01
  day: 01
PublicationDecade 2010
PublicationPlace Cairo, Egypt
PublicationPlace_xml – name: Cairo, Egypt
– name: Egypt
– name: New York
PublicationTitle International Journal of Endocrinology
PublicationTitleAlternate Int J Endocrinol
PublicationYear 2017
Publisher Hindawi Limiteds
Hindawi Publishing Corporation
Hindawi
John Wiley & Sons, Inc
Wiley
Publisher_xml – name: Hindawi Limiteds
– name: Hindawi Publishing Corporation
– name: Hindawi
– name: John Wiley & Sons, Inc
– name: Wiley
References 22
44
45
25
47
26
(33) 2010; 25
(42) 1999; 59
27
29
(37) 2013; 17
(30) 1997; 57
31
10
32
11
12
34
13
35
14
36
(23) 2015; 8
16
38
17
18
19
(24) 2001; 34
(39) 2000; 14
(28) 1992; 59
1
2
3
4
(46) 2011; 1
5
6
(43) 2001; 158
7
(15) 1997; 57
8
9
40
41
20
21
19441017 - Hepatology. 2009 Jul;50(1):113-21
11238046 - Am J Pathol. 2001 Mar;158(3):987-96
10213482 - Cancer Res. 1999 Apr 15;59(8):1811-5
12727994 - J Clin Endocrinol Metab. 2003 May;88(5):2341-7
7533768 - J Clin Endocrinol Metab. 1995 Mar;80(3):1006-11
23783103 - J Clin Endocrinol Metab. 2013 Aug;98(8):E1401-9
20306451 - Int J Biol Markers. 2010 Jan-Mar;25(1):38-45
26808342 - CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
11679179 - Lung Cancer. 2001 Nov;34(2):207-18
18931683 - Nat Med. 2008 Nov;14(11):1271-7
9665469 - Am J Pathol. 1998 Jul;153(1):91-101
9134998 - Cancer Res. 1997 May 1;57(9):1634-7
15836707 - J Gastroenterol Hepatol. 2005 Apr;20(4):583-8
17143292 - Oncogene. 2006 Dec 4;25(57):7482-91
1381547 - Adv Cancer Res. 1992;59:115-65
25594541 - Radiat Res. 2015 Feb;183(2):196-207
23468064 - Hepatology. 2013 Aug;58(2):642-53
24301304 - Cancer. 2013 Dec 15;119(24):4358-65
17914108 - Endocr Relat Cancer. 2007 Sep;14(3):791-8
19240234 - Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91
11288983 - Thyroid. 2001 Feb;11(2):147-52
23487264 - Hepatology. 2013 Aug;58(2):654-66
26280537 - Nat Cell Biol. 2015 Oct;17 (10 ):1348-55
23352645 - Cancer Lett. 2013 Jun 10;333(2):159-69
22016822 - Am J Cancer Res. 2011;1(6):716-25
19167326 - Cell. 2009 Jan 23;136(2):215-33
25403884 - Tumour Biol. 2015 Mar;36(3):2127-34
22739938 - Cell Cycle. 2012 Jul 1;11(13):2495-506
22472564 - J Clin Endocrinol Metab. 2012 Jun;97(6):2084-92
23264400 - J Clin Endocrinol Metab. 2013 Feb;98(2):E196-205
23677575 - Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1252-9
10921899 - Genes Dev. 2000 Aug 1;14 (15):1837-51
12107263 - J Clin Endocrinol Metab. 2002 Jul;87(7):3433-40
19619488 - Dev Cell. 2009 Jul;17(1):9-26
26309570 - Int J Clin Exp Med. 2015 Jun 15;8(6):9142-8
27717302 - Thyroid. 2016 Dec;26(12 ):1733-1743
26650737 - PLoS One. 2015 Dec 09;10 (12 ):e0144073
19016336 - Cancer Causes Control. 2009 Jul;20(5):525-31
23204228 - Cancer Res. 2013 Jan 15;73(2):756-66
27652312 - Mol Cell Oncol. 2015 Dec 10;3(4):e1109744
26345235 - Onco Targets Ther. 2015 Aug 26;8:2271-7
21777817 - Mol Cell. 2011 Jul 22;43(2):285-98
17143293 - Oncogene. 2006 Dec 4;25(57):7492-504
9041202 - Cancer Res. 1997 Mar 1;57(5):963-9
11313997 - Oncogene. 2001 Feb 1;20(5):645-53
16030160 - J Clin Endocrinol Metab. 2005 Oct;90(10):5723-9
23467939 - Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):427-35
References_xml – ident: 21
  doi: 10.1371/journal.pone.0144073
– ident: 4
  doi: 10.1158/1055-9965.EPI-13-0242
– volume: 57
  start-page: 963
  issue: 5
  year: 1997
  ident: 30
  publication-title: Cancer Research
– ident: 7
  doi: 10.1210/jc.2011-3059
– ident: 41
  doi: 10.1038/sj.onc.1210055
– volume: 158
  start-page: 987
  issue: 3
  year: 2001
  ident: 43
  publication-title: The American Journal of Pathology
  doi: 10.1016/S0002-9440(10)64045-X
– volume: 14
  start-page: 1837
  issue: 15
  year: 2000
  ident: 39
  publication-title: Genes & Development
  doi: 10.1101/gad.14.15.1837
– ident: 6
  doi: 10.1016/j.cell.2009.01.002
– ident: 3
  doi: 10.3322/caac.21338
– volume: 1
  start-page: 716
  issue: 6
  year: 2011
  ident: 46
  publication-title: American Journal of Cancer Research
– ident: 38
  doi: 10.1016/j.devcel.2009.06.016
– ident: 22
  doi: 10.1002/hep.26373
– ident: 26
  doi: 10.4161/cc.20898
– ident: 40
  doi: 10.1038/sj.onc.1210056
– ident: 34
  doi: 10.1016/j.canlet.2013.01.028
– ident: 20
  doi: 10.1002/hep.22919
– ident: 44
  doi: 10.1210/jcem.87.7.8648
– ident: 29
  doi: 10.1210/jcem.80.3.7533768
– ident: 16
  doi: 10.1016/j.molcel.2011.06.020
– ident: 45
  doi: 10.1038/nm.1880
– ident: 14
  doi: 10.2147/OTT.S85753
– ident: 27
  doi: 10.1158/0008-5472.CAN-12-2651
– volume: 59
  start-page: 115
  year: 1992
  ident: 28
  publication-title: Advances in Cancer Research
  doi: 10.1016/S0065-230X(08)60305-X
– ident: 47
  doi: 10.1038/sj.onc.1204123
– volume: 25
  start-page: 38
  issue: 1
  year: 2010
  ident: 33
  publication-title: The International Journal of Biological Markers
  doi: 10.1177/172460081002500106
– ident: 36
  doi: 10.1038/ncb3222
– ident: 32
  doi: 10.1210/jc.2002-021113
– ident: 18
  doi: 10.1210/jc.2012-2666
– ident: 11
  doi: 10.1667/RR13784.1
– ident: 31
  doi: 10.1111/j.1440-1746.2005.03726.x
– ident: 10
  doi: 10.1089/thy.2015.0578
– ident: 1
  doi: 10.1158/1055-9965.EPI-08-0960
– ident: 17
  doi: 10.1016/S0002-9440(10)65549-6
– volume: 8
  start-page: 9142
  issue: 6
  year: 2015
  ident: 23
  publication-title: International Journal of Clinical and Experimental Medicine
– ident: 9
  doi: 10.1002/cncr.28254
– ident: 13
  doi: 10.1002/hep.26378
– ident: 2
  doi: 10.1007/s10552-008-9260-4
– volume: 57
  start-page: 1634
  issue: 9
  year: 1997
  ident: 15
  publication-title: Cancer Research
– ident: 5
  doi: 10.1210/jc.2005-0285
– volume: 34
  start-page: 207
  issue: 2
  year: 2001
  ident: 24
  publication-title: Lung Cancer
  doi: 10.1016/S0169-5002(01)00225-2
– ident: 8
  doi: 10.1210/jc.2013-1214
– ident: 25
  doi: 10.1089/105072501300042802
– ident: 35
  doi: 10.1007/s13277-014-2822-z
– volume: 17
  start-page: 427
  issue: 4
  year: 2013
  ident: 37
  publication-title: European Review for Medical and Pharmacological Sciences
– ident: 12
  doi: 10.1080/23723556.2015.1109744
– volume: 59
  start-page: 1811
  issue: 8
  year: 1999
  ident: 42
  publication-title: Cancer Research
– ident: 19
  doi: 10.1677/ERC-07-0129
– reference: 23487264 - Hepatology. 2013 Aug;58(2):654-66
– reference: 11679179 - Lung Cancer. 2001 Nov;34(2):207-18
– reference: 17143293 - Oncogene. 2006 Dec 4;25(57):7492-504
– reference: 11238046 - Am J Pathol. 2001 Mar;158(3):987-96
– reference: 26808342 - CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
– reference: 23677575 - Cancer Epidemiol Biomarkers Prev. 2013 Jul;22(7):1252-9
– reference: 1381547 - Adv Cancer Res. 1992;59:115-65
– reference: 27717302 - Thyroid. 2016 Dec;26(12 ):1733-1743
– reference: 26309570 - Int J Clin Exp Med. 2015 Jun 15;8(6):9142-8
– reference: 17143292 - Oncogene. 2006 Dec 4;25(57):7482-91
– reference: 22016822 - Am J Cancer Res. 2011;1(6):716-25
– reference: 23352645 - Cancer Lett. 2013 Jun 10;333(2):159-69
– reference: 26345235 - Onco Targets Ther. 2015 Aug 26;8:2271-7
– reference: 7533768 - J Clin Endocrinol Metab. 1995 Mar;80(3):1006-11
– reference: 10921899 - Genes Dev. 2000 Aug 1;14 (15):1837-51
– reference: 25594541 - Radiat Res. 2015 Feb;183(2):196-207
– reference: 9041202 - Cancer Res. 1997 Mar 1;57(5):963-9
– reference: 27652312 - Mol Cell Oncol. 2015 Dec 10;3(4):e1109744
– reference: 19240234 - Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91
– reference: 15836707 - J Gastroenterol Hepatol. 2005 Apr;20(4):583-8
– reference: 20306451 - Int J Biol Markers. 2010 Jan-Mar;25(1):38-45
– reference: 11288983 - Thyroid. 2001 Feb;11(2):147-52
– reference: 11313997 - Oncogene. 2001 Feb 1;20(5):645-53
– reference: 23264400 - J Clin Endocrinol Metab. 2013 Feb;98(2):E196-205
– reference: 23468064 - Hepatology. 2013 Aug;58(2):642-53
– reference: 23467939 - Eur Rev Med Pharmacol Sci. 2013 Feb;17(4):427-35
– reference: 24301304 - Cancer. 2013 Dec 15;119(24):4358-65
– reference: 22472564 - J Clin Endocrinol Metab. 2012 Jun;97(6):2084-92
– reference: 19016336 - Cancer Causes Control. 2009 Jul;20(5):525-31
– reference: 9134998 - Cancer Res. 1997 May 1;57(9):1634-7
– reference: 18931683 - Nat Med. 2008 Nov;14(11):1271-7
– reference: 23204228 - Cancer Res. 2013 Jan 15;73(2):756-66
– reference: 12107263 - J Clin Endocrinol Metab. 2002 Jul;87(7):3433-40
– reference: 22739938 - Cell Cycle. 2012 Jul 1;11(13):2495-506
– reference: 17914108 - Endocr Relat Cancer. 2007 Sep;14(3):791-8
– reference: 19441017 - Hepatology. 2009 Jul;50(1):113-21
– reference: 12727994 - J Clin Endocrinol Metab. 2003 May;88(5):2341-7
– reference: 10213482 - Cancer Res. 1999 Apr 15;59(8):1811-5
– reference: 25403884 - Tumour Biol. 2015 Mar;36(3):2127-34
– reference: 26280537 - Nat Cell Biol. 2015 Oct;17 (10 ):1348-55
– reference: 9665469 - Am J Pathol. 1998 Jul;153(1):91-101
– reference: 19619488 - Dev Cell. 2009 Jul;17(1):9-26
– reference: 19167326 - Cell. 2009 Jan 23;136(2):215-33
– reference: 21777817 - Mol Cell. 2011 Jul 22;43(2):285-98
– reference: 16030160 - J Clin Endocrinol Metab. 2005 Oct;90(10):5723-9
– reference: 26650737 - PLoS One. 2015 Dec 09;10 (12 ):e0144073
– reference: 23783103 - J Clin Endocrinol Metab. 2013 Aug;98(8):E1401-9
SSID ssj0066601
Score 2.287616
Snippet Background. MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the...
Background . MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the...
MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and was verified to be downregulated in PTC by the large data set...
MicroRNA (miRNA) dysregulation was commonly seen in papillary thyroid carcinoma (PTC), and miR-195 was verified to be downregulated in PTC by the large data...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
hindawi
emarefa
airiti
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 1
SubjectTerms Antibodies
Antigens
Cell adhesion & migration
Cloning
Development and progression
Endocrinology
Genes
Genetic aspects
Medical prognosis
Metastasis
MicroRNA
MicroRNAs
Pathogenesis
Plasmids
Thyroid cancer
SummonAdditionalLinks – databaseName: Directory of Open Access Journals - May need to register for free articles
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3fb9MwELbQJCReEDB-ZBQw0oAHFC1OYid5LIFuIDpNqJP2Ztmxo0Zq06lNhfrfc-ek2TKB9sJLqtRWUsfnu-9Lz98RcsywGFJsCt-EmvtxJJSvbWl8owOMPgCwS9ycPD0XZ5fxjyt-davUF-aEtfLA7YM74UWYWhWJMi1YXGqeKgx5CFvgmLot6yHEvD2Zan0wYHJX-Bh-B_jgKEr2Ke-cA9tnyYlgKVorhB1VoXjQICo58X63Q1fBueqd9cM50uTf1d_A6N2cyltBavKEPO7QJR23o3pKHtj6GTkc18Cslzv6kbp8T_ci_ZCsp9Uvn2Wcfq_nla6aDZ1tl6s1PQVi3sypqg2d2kYBetxUG1rV9EJdY4mi9Y7O5rv1qjI0x0JE9WqpaG4XC_oTU-iphnaXXg5Bkeb5-VfmrjU5nYTPyeXk2yw_87sKDL4SImn8hJsyVLCkU2XSQCfGFbNSkc00wIJAoRi9BQIDrCeLkXqA_ywFsyxCVX0WRC_IQb2q7StCA83jSBWZAoiHApUALANtTBFGKlaRMh6ZtFMhu0W0kRchyt9lAFmCUOK0MfeRAmJB5ag7J0zCAciqRz7vp1IWnc45lttYSMd3OHeXkp0FeORD3_u61ff4R78vaBV9H1Tldl-ArcrOVuV9tuqRl51N3dyLCQEc1SPv0MZku_m19zpyDIAa3GaKw_rkeqDfgeEUqts-AU8XFbwGPUeDnuAvikHzcWfH9wx4tDfymxkBuIf6QkJA8_u-GW-AqXq1XW030lEGhv83w3DbNdHfCIsrBMBAPJIMVsvgsQ5b6mruRM-BScfANY7-xzy8Jo9wqO2btBE5aNZb-wawZaPfOjfyB-MmZIY
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Hindawi Publishing Open Access
  dbid: RHX
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1db9MwFLXYJCReEGN8ZBQw0oAHFBHnw0kfS6EriE4T6qS-WXbsKJHadGpSTf333OukGSkgeEnl2o1r-_r6nMQ-l5BzhsGQQp262leRGwZcuspk2tXKw9UHAHaGh5Nnl3x6HX5bRItWJKn6_RU-rHZAz1n8kbMEzeuIHIGBISmfLvYOFwC4jXIMlYLDDYJ4v7_94LewxsgClYJ6S5BV6rfHcSWkZeeZ7-fIiW-LPyHPww2Uv6xIk0fkYQsl6agZ-xNyz5SPyemoBBq92tF31G7utE_NT8lmVvxw2TCiX8u8UEVd0fl2td7QC2DhdU5lqenM1BKgYlVUtCjplbzBeESbHZ3nu8260HSMUYfK9UrSsVku6XfcL08V5Nu95LAC0vH48jOz95pcTPwn5HryZT6eum24BVdyHtduHOnMl9C9idSJp2JtI1fJwAwVYABPovK8AbYCFGcYIs8AZ5lxZliAEvrMC56S43JdmueEeioKA5kOJeA5VKMEFOkprVM_kKEMpHbIpBkK0c6YSlz5qHU3BHzi-QKHjdmPBOAJykQdJJiACzBTh3zYD6VIW1FzjK2xFJbcRJG9lWgtwCFvu9I3jZjHX8p9QqvoyqAEt_0CzFK0M1pEqZ8YGfAsSVmYqSiRiMUQT8M1CZlDnrU2dVcX4xwIqUNeo42J5qRr52LECNAz-MgEm_XelkAnA81JZXtWAnoX5bp6JQe9kuAc0l72eWvH_2jwYG_kdyMC2A7FhDiH7DddNlaA-_JKs95WwvIDhi-XobnNnOgqwkgKHtANh8S92dLr1n5OWeRW4RxocwjE4uz__v0L8gCTzYOxATmuN1vzEqBirV5ZR_ETXIBTDw
  priority: 102
  providerName: Hindawi Publishing
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV1Lj9MwELZgERIXBCyPQAEjLXBA0cZ594RKobsgulqhrtSbZccJidQmJUmF-u-ZcdyUrHhcUqW2kjgej7_PGX9DyAnDZEi-SmzlysD2vVDYMs2UraSDsw8A7Aw3J88vwvMr_8syWJoFt8aEVe59onbUqkpwjfwUZhqUNgnD4P3mh41Zo_DrqkmhcZPcQukytOpo2RMuQOY6_TE8DXhiz4v2ge9BAJyfRachi9FmYfIRBUoIDeYmLeGv9-kKOBe9y76dI1n-WfwJkl6PrPxtqprdI3cNxqSTzijukxtp-YAcT0rg1-sdfUN11KdeTj8m9bz4ZkOj6OcyL2TRNnSxXVc1PQN63uZUlIrO01YAhmyKhhYlvRQbTFRU7-gi39VVoegU0xGV1VrQabpa0a8YSE8llOsgc5ga6XR68ZHpa83OZu5DcjX7tJie2yYPgy3CMGrtKFCZK2Bgx0LFjoyUTmklvHQsARw4AiXpU6AxwH3GPhIQ8KJZyFLmobY-c7xH5KisyvQJoY4MfE8kYwFAD2UqAV46UqnE9YQvPKEsMuu6gpuh1PBLF0XwxgBcHJdjtzH9EwNuQf2oayeMwwEoq0Xe7buSJ0btHJNurLhmPUGgL8WNBVjkdV9706l8_KXeB7SKvg5qc-s_qvo7N0OdB4kbp8ILszhhfiaDWCBIQ6ANx9hnFnlsbOpwL7BrYKoWeYk2xrstsL3v4ROA1eA8Y2zWW10DvQ80JxFmEwW8XdTxGtQcDWqC10gGxSfGjv_T4NHeyA89chiKFnnVF-MNMGCvTKttwzVxYPjVGZrbjYn-RphiwQEeYpFoMFoGr3VYUha5lj4HPu0D43j678d6Ru5gI7qVshE5autt-hywYytfaAfxC8EvXVA
  priority: 102
  providerName: ProQuest
Title MiR-195 Inhibits Tumor Growth and Metastasis in Papillary Thyroid Carcinoma Cell Lines by Targeting CCND1 and FGF2
URI https://www.airitilibrary.com/Article/Detail/P20160919002-201712-201811010012-201811010012-1-12-094
https://search.emarefa.net/detail/BIM-1166495
https://dx.doi.org/10.1155/2017/6180425
https://www.ncbi.nlm.nih.gov/pubmed/28740507
https://www.proquest.com/docview/2410481665
https://www.proquest.com/docview/1923113858
https://pubmed.ncbi.nlm.nih.gov/PMC5504932
https://doaj.org/article/5c28ea36f8c14fb58a43173977173841
Volume 2017
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bj9JAFJ7sRRNfjLpeqohjsuqD6dppO215MIbFBTRCCIGEt8n0Jk2gXUuJ8u89Z2i7lqwx8WUIzLRlOuec-b525juEnDNMhmSHgR6aPtdty5G6H8WhHvoGzj4AsGPcnDwaO8O5_XXBF0ekyjZa3sDNrdQO80nN89XFrx-7T-DwH5XDcw78nbkfHOah_R2TU5iTXMxlMLLr9wmA0VUiZPhfEJMty62WwB8cjdLAmKOOY3bZOzJBXaHGhKV0_dXmXQnfZR3H7y6RQf9MbsOph8st_5i_-g_I_RJ40u7eUh6Soyh9RM66KZDu9Y6-pWopqHrGfkbyUTLVWYfTL-ky8ZNiQ2fbdZbTAXD2YkllGtJRVEgAlptkQ5OUTuQ1Zi_Kd3S23OVZEtIe5ihKs7WkvWi1ot9wdT31oV6tPIf5kvZ6489Mnas_6JuPybx_NesN9TI5gy4dxy10l4exKcHbPRl6hu-GKs-VtKKOD4jBkKhTHwG3AULUsZGVQGiNHRYxCwX3mWE9ISdplkbPCDV8blsy6EhAf6hdCZjT8MMwMC1pS0uGGunvh0JU5iEmJirjdQDNGKbAEWTqwwMwg6JSB1-YgAJ4rEbeV0MpglICHTNxrISiQpyrU4nSGDTypm59vZf--Eu7S7SKug0Kdqsfsvy7KP1f8MD0Imk5sRcwO_a5JxG5IfqG0rOZRp6WNnVzLeY4QF818gptTOz3xdYBSXQBa0NE9bBb71QLdBLoTiDLnRVwd1Hcq9Gy1WgJoSRoVJ-XdvyPDrcqI78ZEfA6lB5yHKh-XVfjBXAVXxpl241QbILhq2jo7t4n6gtVfqcRt-EtjdvarEmTpdJDB5JtAw15_t9HviD3sH_7J2stclLk2-glYM3Cb5Njd-G2yenl1XgybasnNlAOFqytAgyU0-HiN1pzcdw
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VIgQXBJSHIdBFauGArPq1jnNAKKSkCU2qCqVSbtu11yaWEjvYjqL8KX4jM2vHwRWPUy-Okl3ZWe_szPfZs98QcmRiMSRHBrq0fKY7tit0P4ykLn0Dow8A7Ag3J48v3MGV83XKpnvk53YvDKZVbn2ictQyDfAZ-QlEGpQ2cV32aflDx6pR-HZ1W0KjNIvzcLMGypZ_HJ7C_B5bVv_LpDfQq6oCunDddqG3mYwsAWbqCekZfluqAk3CDjs-hDpDoMB6CKAckDyWn2ce-ITINUPTRqV407DhvHfIXQi8BpK99rQmeMAEVLllGD14fttubxPtGTuxUKfaNT1cIxDsRIySRY1YqEoGqH3BAr6LOkTcmyE5X8d_gsA3Mzl_C439R-RhhWlptzTCx2QvTJ6Qg24CfH6xoe-oyjJVj-8PSDaOv-lmh9FhMov9uMjpZLVIM3qWpetiRkUi6TgsBGDWPM5pnNBLscTCSNmGTmabLI0l7WH5oyRdCNoL53M6wsR96kO7SmqHUEx7vYtTU52rf9a3npKrW5mhZ2Q_SZPwBaGGzxxbBB0BwBJlMQHOGr6UgWULR9hCaqRfTgWvlm7OLy0U3esAUDIsjtNmqg8PcBLqVd34YnI4AEXWyIftVPKgUlfHIh9zrlgWY-pUvLIAjRzXvZelqshf-n1Gq6j7oBa4-iHNvvPKtXAWWF4obDfyAtOJfOYJBIUI7OHoOaZGnlc2tbsWrCNgxho5RBvj5Zbb2tfxLsB4cNYeDuu96oHeDoYTiGrTBtxd1A1r9Gw1eoKXChrNR5Ud_2fAra2R72Zkt_Q18rZuxgtggmASpqucK6Ji4ltuGG65JuoLYUkHA3iPRtqN1dK4rc2WJJ4pqXXg7w4wnJf__luH5P5gMh7x0fDi_BV5gAMqn9K1yH6RrcLXgFsL_41yFpRc37Z3-gU3ZJZl
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9owELc6qk17mbZ1H9nY6knt9jBF5MshPEwThdKyFoQqKvXNdeJkRIKEBRDiX9tftzsngaXax1NfgoKtOLbPd79zzr8j5MjEZEiODHRp-Ux3bFfofhhJXfoGWh8A2BEeTh4M3fNr59sNu9kjP8uzMBhWWepEpahlGuAeeQMsDVKbuC5rREVYxKjb-zr_oWMGKfzSWqbTyEXkItyswX1bfOl3Ya6PLat3Ou6c60WGAV24bnOpN5mMLAEi6wnpGX5TqmRNwg5bPpg9QyDZeggAHVA9pqJnHuiHyDVD00bWeNOw4bkPyH4TvaIa2T85HY6uSjsAfoFKvgxjAXbAtptl2D1jDQtZq13TwxUDpk_ESGBUsYwqgYA6JSzgXmwNxsMJuurr-E-A-G5c52-GsveUPCkQLm3nIvmM7IXJc3LQTsC7n23oR6piTtVm_gHJBvGVbrYY7SeT2I-XCzpezdKMnmXpejmhIpF0EC4FINhFvKBxQkdijmmSsg0dTzZZGkvawWRISToTtBNOp_QSw_ipD-UqxB0MM-10hl1TPat31rNekOt7maOXpJakSfiaUMNnji2ClgCYiSSZAG4NX8rAsoUjbCE10sunghcLecFHFlLwtQA2GRbHaTPVjweoCdmr7tyYHC7gMGvkczmVPCi41jHlx5Qrn4sx9SheSIBGjre15znHyF_qnaBUbOsgM7j6I82-80LRcBZYXihsN_IC04l85gmEiAjz4eo5pkZeFTK1awtWFfjJGjlEGeP5Adyt5uNtAPWguj3s1idVA3UfdCcQxREOGF1kEavUrFdqgs4KKsVHhRz_p8P1Ush3M7JTBBr5sC3GBjBcMAnT1YIrt8XEb97Q3XxNbBvCBA8GeEEaaVZWS2VYqyVJPFHE6-DNO-DvvPn3ax2SR6CZ-GV_ePGWPMb-5Ft2dVJbZqvwHYDYpf--0BaU3N63gvoFc9GcAA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=MiR-195+Inhibits+Tumor+Growth+and+Metastasis+in+Papillary+Thyroid+Carcinoma+Cell+Lines+by+Targeting+CCND1+and+FGF2&rft.jtitle=International+journal+of+endocrinology&rft.au=Yin%2C+Yali&rft.au=Hong%2C+Shubin&rft.au=Yu%2C+Shuang&rft.au=Huang%2C+Yanrui&rft.date=2017-01-01&rft.pub=Hindawi&rft.issn=1687-8337&rft.eissn=1687-8345&rft.volume=2017&rft_id=info:doi/10.1155%2F2017%2F6180425&rft_id=info%3Apmid%2F28740507&rft.externalDocID=PMC5504932
thumbnail_m http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fwww.airitilibrary.com%2Fjnltitledo%2FP20160919002-c.jpg